These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 30467049)

  • 1. Bilateral Vocal Cord Paralysis: Pembrolizumab-Induced Delayed-Onset Toxicity in a Patient with Lung Adenocarcinoma.
    Hamada S; Okamoto N; Tsukino M
    J Thorac Oncol; 2018 Dec; 13(12):e257-e259. PubMed ID: 30467049
    [No Abstract]   [Full Text] [Related]  

  • 2. Psuedoprogression mimicking hyperprogressive disease after pembrolizumab treatment in a patient with lung cancer.
    Hashimoto K; Kaira K; Kawasaki T; Yamaguchi O; Kagamu H
    Lung Cancer; 2020 Jan; 139():221-223. PubMed ID: 31806361
    [No Abstract]   [Full Text] [Related]  

  • 3. Pembrolizumab induced toxic epidermal necrolysis.
    Kumar R; Bhandari S
    Curr Probl Cancer; 2020 Apr; 44(2):100478. PubMed ID: 31122669
    [No Abstract]   [Full Text] [Related]  

  • 4. Hyperprogressive Disease in Lung Cancer with Transformation of Adenocarcinoma to Small-cell Carcinoma during Pembrolizumab Therapy.
    Okeya K; Kawagishi Y; Muranaka E; Izumida T; Tsuji H; Takeda S
    Intern Med; 2019 Nov; 58(22):3295-3298. PubMed ID: 31327828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholestatic Liver Injury Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma.
    Kurokawa K; Hara M; Iwakami SI; Genda T; Iwakami N; Miyashita Y; Fujioka M; Sasaki S; Takahashi K
    Intern Med; 2019; 58(22):3283-3287. PubMed ID: 31735738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report.
    Sugano T; Seike M; Funasaka Y; Yoshida M; Takayama R; Okamura K; Nakanishi A; Tanaka T; Takeuchi S; Noro R; Minegishi Y; Kubota K; Saeki H; Gemma A
    J Immunother Cancer; 2019 Feb; 7(1):59. PubMed ID: 30813943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pseudoprogression and Rapid Response to Pembrolizumab in a Patient with Advanced Lung Adenocarcinoma with Loss of Epidermal Growth Factor Receptor Gene Mutation after Tyrosine Kinase Inhibitor Therapy.
    Yamaura T; Suzuki H
    J Thorac Oncol; 2018 Oct; 13(10):e209-e210. PubMed ID: 30244857
    [No Abstract]   [Full Text] [Related]  

  • 8. Psoriatic arthritis induced by anti-programmed death 1 antibody pembrolizumab.
    Hara T; Mikita N; Ikeda T; Inaba Y; Kunimoto K; Kaminaka C; Kanazawa N; Yamamoto Y; Jinnin M
    J Dermatol; 2019 Dec; 46(12):e466-e467. PubMed ID: 31376178
    [No Abstract]   [Full Text] [Related]  

  • 9. Pembrolizumab-Induced Rhabdomyolysis With Myositis in a Patient With Lung Adenocarcinoma.
    Hamada S; Fuseya Y; Tsukino M
    Arch Bronconeumol (Engl Ed); 2018 Jun; 54(6):346-348. PubMed ID: 29496287
    [No Abstract]   [Full Text] [Related]  

  • 10. Pericardial tamponade during pembrolizumab treatment in a patient with advanced lung adenocarcinoma: A case report and review of the literature.
    Harada K; Ogasawara M; Shido A; Meno A; Oda S; Yoshida S; Yoshida S; Yoshikawa A; Ebata K; Abiko S; Kawagishi N; Sano I; Oda H; Miyagishima T
    Thorac Cancer; 2020 May; 11(5):1350-1353. PubMed ID: 32181993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin induced reversible bilateral vocal cord paralysis: an undescribed complication of cisplatin.
    Taha H; Irfan S; Krishnamurthy M
    Head Neck; 1999 Jan; 21(1):78-9. PubMed ID: 9890355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Life threatening pembrolizumabinduced myositis in a patient treated for advanced adenocarcinoma of the lung.
    Robinson SD; Lai C; Hotton G; Anand G
    Acute Med; 2019; 18(3):197-199. PubMed ID: 31536059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to pembrolizumab in a patient with primary lung adenocarcinoma originated from indium lung.
    Sekine Y; Ichimura H; Ueda S; Kobayashi K; Nawa T; Amata A; Chonan T; Sakata A; Komatsu Y; Sato Y
    BMC Pulm Med; 2021 Mar; 21(1):107. PubMed ID: 33789640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperprogression after first dose of immunotherapy in a patient with radioresistant metastasis from nonsmall cell lung cancer.
    Bosch-Barrera J; Oliva E; Sais E; Vásquez CA; Roselló A; Menéndez JA
    Anticancer Drugs; 2019 Nov; 30(10):1067-1070. PubMed ID: 31567311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolated Hypogonadotropic Hypogonadism Secondary to Anti-Programmed Death Ligand 1 Inhibitor.
    Davies A; Naderpoor N; Parakh S
    J Thorac Oncol; 2019 Jul; 14(7):e147-e148. PubMed ID: 31235040
    [No Abstract]   [Full Text] [Related]  

  • 16. Carboplatin, pemetrexed, and pembrolizumab was effective for primary salivary gland-type lung adenocarcinoma diagnosed due to esophageal stricture: A case report.
    Kawakado K; Tamura T; Nakanishi M; Makimoto G; Sato Y; Kuyama S
    Thorac Cancer; 2021 Sep; 12(18):2513-2516. PubMed ID: 34369074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lung adenocarcinoma initially presenting as Trousseau's syndrome treated successfully with pembrolizumab: A case report.
    Nakano Y; Koide N; Koyama Y; Nitta K; Koizumi T
    Thorac Cancer; 2021 Feb; 12(4):557-559. PubMed ID: 33350050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Metastatic lung adenocarcinoma. Nivolumab as second line treatment: between unresolved issues and promising future. A case report.].
    Cortinovis DL
    Recenti Prog Med; 2018 Mar; 109(3):197e-201e. PubMed ID: 29565054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sarcoid-like reaction of the extrathoracic lymph node in a patient with lung adenocarcinoma treated with pembrolizumab.
    Takamori S; Furubayashi N; Taguchi K; Matsubara T; Fujishita T; Ito K; Yamaguchi M; Toyozawa R; Seto T; Negishi T; Nakamura M; Okamoto T
    Thorac Cancer; 2021 Jul; 12(14):2122-2125. PubMed ID: 34002950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged response after the discontinuation of nivolumab after resistance to gefitinib.
    Sasatani Y; Okauchi S; Ohara G; Kagohashi K; Satoh H
    Clin Respir J; 2019 Oct; 13(10):657-658. PubMed ID: 31343829
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.